The origin of the myofibroblast in fibrotic lung disease is uncertain, and no effective medical therapy for fibrosis exists. We have previously demonstrated that transforming growth factor-b1 (TGF-b1) induces pleural mesothelial cell (PMC) transformation into myofibroblasts and haptotactic migration in vitro. Whether PMC differentiation and migration occurs in vivo, and whether this response can be modulated for therapeutic benefit, is unknown. Here, using mice recombinant for green fluorescent protein (GFP) driven by the Wilms tumor-1 (WT-1) promoter, we demonstrate PMC trafficking into the lung and differentiation into myofibroblasts. Carbon monoxide or the induction of heme oxygenase-1 (HO-1) inhibited the expression of myofibroblast markers, contractility, and haptotaxis in PMCs treated with TGF-b1. Intrapleural HO-1 induction inhibited PMC migration after intratracheal fibrogenic injury. PMCs from patients with idiopathic pulmonary fibrosis (IPF) exhibited increased expression of myofibroblast markers and enhanced contractility and haptotaxis, compared with normal PMCs. Carbon monoxide reversed this IPF PMC profibrotic phenotype. WT-1eexpressing cells were present within fibrotic regions of the lungs in IPF subjects, supporting a role for PMC differentiation and trafficking as contributors to the myofibroblast population in lung fibrosis. Our findings also support a potential role for pleuralbased therapies to modulate pleural mesothelial activation and parenchymal fibrosis progression. Idiopathic pulmonary fibrosis (IPF), the most common idiopathic interstitial pneumonia, is characterized by cellular and structural changes in the parenchyma associated with the proliferation of myofibroblasts and deposition of extracellular matrix components.
The origin of the myofibroblast in fibrotic lung disease is uncertain, and no effective medical therapy for fibrosis exists. We have previously demonstrated that transforming growth factor-b1 (TGF-b1) induces pleural mesothelial cell (PMC) transformation into myofibroblasts and haptotactic migration in vitro. Whether PMC differentiation and migration occurs in vivo, and whether this response can be modulated for therapeutic benefit, is unknown. Here, using mice recombinant for green fluorescent protein (GFP) driven by the Wilms tumor-1 (WT-1) promoter, we demonstrate PMC trafficking into the lung and differentiation into myofibroblasts. Carbon monoxide or the induction of heme oxygenase-1 (HO-1) inhibited the expression of myofibroblast markers, contractility, and haptotaxis in PMCs treated with TGF-b1. Intrapleural HO-1 induction inhibited PMC migration after intratracheal fibrogenic injury. PMCs from patients with idiopathic pulmonary fibrosis (IPF) exhibited increased expression of myofibroblast markers and enhanced contractility and haptotaxis, compared with normal PMCs. Carbon monoxide reversed this IPF PMC profibrotic phenotype. WT-1eexpressing cells were present within fibrotic regions of the lungs in IPF subjects, supporting a role for PMC differentiation and trafficking as contributors to the myofibroblast population in lung fibrosis. Our findings also support a potential role for pleuralbased therapies to modulate pleural mesothelial activation and parenchymal fibrosis progression. Idiopathic pulmonary fibrosis (IPF), the most common idiopathic interstitial pneumonia, is characterized by cellular and structural changes in the parenchyma associated with the proliferation of myofibroblasts and deposition of extracellular matrix components. 1 IPF begins in the subpleural region and extends centrally, resulting in a progressive decline in lung function. The origin of the pathogenic myofibroblast is uncertain. The hallmark lesions of IPF, the fibroblastic foci seen on two-dimensional histopathological slides, were thought of as discrete sites of epithelial injury and repair. 2 Cool et al 3 used three-dimensional reconstruction to demonstrate that these foci are part of a complex, highly interconnected reticulum and suggested the leading edge of the fibroblastic invasion extends from the pleura to the underlying parenchyma like a wave of fibrosis.
The pleura is a metabolically active monolayer of mesothelial cells that intimately approximates the lung parenchyma. The close proximity of PMCs to the underlying lung ideally positions them to respond to cytokines, chemokines, and growth factors released during parenchymal stress, injury, infection, or inflammation. The cytokine transforming growth factor-b1 (TGF-b1) is a crucial mediator of epithelialemesenchymal transition (EMT) and acts as a master switch for induction of fibrosis in many organs, including the lung.
4e6 PMC transformation into myofibroblasts and haptotactic migration occur in vitro in response to TGF-b1. 7 The concept of pleural mesothelialemesenchymal transition (MMT) was investigated in a recent study demonstrating PMC migration into the lung and expression of myofibroblast phenotypic markers. This study demonstrated the presence of PMCs in the lung parenchyma of patients with IPF and a correlation with disease severity and the degree of fibrosis.
8
PMC differentiation into myofibroblasts and subsequent migration may play a crucial role in the development of fibrotic lung disease.
Heme oxygenase-1 (HO-1) is the inducible form of the ratelimiting enzyme involved in the degradation of heme with the generation of equimolar quantities of carbon monoxide (CO), iron, and biliverdin. 9 HO-1 induction with subsequent CO production is highly sensitive to numerous stimuli and cellular insults that cause oxidative stress. 10 Such induction represents a beneficial response to injurious stimuli in diverse diseases, including atherosclerosis, sepsis, and fibrosis. The protective effects of HO-1 and CO are due to anti-inflammatory, antiapoptotic, antioxidant, and antiproliferative properties. 11 Indeed, HO-1 deficiency has been associated with increased fibrosis, tubular TGF-b1 expression, inflammation, and enhanced EMT in a model of obstructive kidney disease. 12 Upregulation of HO-1 provides protection against renal injury after unilateral ureteral obstruction and suppression of tubulointerstitial fibrosis via anti-apoptotic pathway modulation. 13 Additionally, adenoviral transfer of the HO-1 gene, as well as administration of CO and bilirubin, has been associated with suppression of fibrosis in animal models of fibrotic lung disease.
14, 15 Here, we present definitive evidence for the presence of PMCs in the lung parenchyma of patients with IPF and show that the fibrotic disposition of these cells can be reversed by CO and HO-1 pathway modulation in vitro. Furthermore, using animal models of lung injury, we demonstrate PMC differentiation into myofibroblasts and parenchymal invasion that is inhibited by intrapleural HO-1 induction.
Materials and Methods

Cell Culture
Mouse wild-type PMCs of passages between 15 and 35 were used. Cells were grown in F12K medium (catalog no. 11765-054; Life TechnologieseInvitrogen, Carlsbad, CA) supplemented with heat-inactivated fetal bovine serum (10%) or in serum-free conditions before (16 hours) and during TGF-b1 treatments. Human PMCs were derived from lung explants from patients diagnosed with IPF undergoing lung transplantation. Cells were cultured in Medium 199 (catalog no. 11150-059; Life TechnologieseInvitrogen) supplemented with epidermal growth factor (EGF) and 10% fetal bovine serum or in serum-free conditions without EGF before and during TGF-b1 exposure.
Cytokine Treatments
Cells were serum-starved for 16 hours and then were treated with 5 ng/mL TGF-b1 (catalog no. 101-B1; R&D Systems, Minneapolis, MN) activated in 4 mmol/L HCl, 0.5% bovine serum albumin.
Induction of HO-1
Cells were treated with 5 mmol/L hemin in dimethyl sulfoxide (catalog no. 51280-1G; Sigma-Aldrich, St. Louis, MO) in either serum-free conditions or in 10% fetal bovine serum medium, depending on the experimental design. Cells were treated with 2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDOIm) at doses of 25 nmol/L or 50 nmol/L, depending on the experiment. The CDDO-Im was provided by Michael Sporn and Karen Liby of Dartmouth Medical School.
CO Treatment
Tricarbonyldichlororuthenium (II) (CORM-2) was purchased from Sigma-Aldrich (catalog no. 288144-500 MG). Cells were exposed to CORM-2 dissolved in dimethyl sulfoxide (10 mmol/L), which served as a source of CO.
Collagen Gel Contraction
Transformed normal pleural mesothelial cells (Met5A) or PMCs from patients with IPF were seeded at a density of 1 Â 10 6 cells/mL. Cells and serum medium were mixed with rat tail collagen reconstituted in 0.1 mol/L acetic acid (catalog no. C7661-50 MG; Sigma-Aldrich) in a 3:1 proportion and seeded in individual wells in a 24-well culture dish. Cells were allowed to acclimatize for 16 hours and then were pretreated with hemin, CDDO-Im, or CORM-2 for 30 minutes, followed by addition of 5 ng/mL TGF-b1; cells were allowed to contract for 48 hours.
Western Blotting
All protein isolates were prepared with radioimmunoprecipitation assay buffer. Samples were sonicated at 4 C, followed by centrifugation to remove insoluble material, and then were subjected to protein assay using a Micro BCA kit (Pierce; Thermo Fisher Scientific, Rockford, IL). All protein levels were adjusted to identical concentrations, followed by reducing with 0.1 mol/L dithiothreitol and resolved on 4 to 20% NuPAGE minigels (catalog no. NP0320; Life TechnologieseInvitrogen) using a morpholine propane sulfonic acid (NP0001) buffer system; samples were then transferred to nitrocellulose membrane (catalog no. 162-0115; Bio-Rad Laboratories, Hercules, CA), followed by blocking in 5% nonfat dry milk reconstituted in Tris-buffered saline/ Tween (pH 7.4) (TBST). The following antibodies were used for immunoblotting: a-SMA mouse monoclonal (1:1000; catalog no. 03-61001; American Research Products, Belmont, MA), b-actin mouse monoclonal (1:2000; catalog no. A5441; Sigma-Aldrich), HO-1 rabbit polyclonal (1:1000; catalog no. ADI-SPA-895; Enzo Life Sciences International, Plymouth Meeting, PA), horseradish peroxidase conjugated a-rabbit IGG (1:5000; catalog no. 31462; Thermo Fisher Scientific), a-mouse IGM (1:5000; catalog no. 31432; Thermo Fisher Scientific), and NOX-4 (catalog no. NB110-58849; ajp.amjpathol.org -The American Journal of Pathology Novus Biologicals). All primary antibodies were prepared in 5% nonfat dry milk reconstituted in TBST (pH 7.4) and probed overnight at 4 C, followed by three washes and then incubation with appropriate horseradish peroxidase conjugated secondary antibody at room temperature for 2 hours. The immunoblots were then washed five times in TBST, followed by developing with chemiluminescent substrate application (Pierce ECL, catalog no. 32106; Thermo Fisher Scientific).
Mouse Models
To investigate the effects of HO-1 during bleomycin injury, we used a pleural delivery model in wild-type and Hmox À/À mice on a C57BL/6J background. To track PMCs, we used a transgenic mouse model that constitutively expresses GFP in Wt1-expressing cells (Wt1 tm1(EGFP/cre)Wtp /J).
Cell Migration Assays
Haptotaxis assays were performed in Costar Transwell migration chambers (Corning Life Sciences, Corning, NY) as described previously, with modifications. 7 In brief, the lower sides of the filters were coated with 1 mg/mL bovine serum albumin, or TGF-b1, or were left untreated and kept overnight at 37 C in humidified air in the presence of 5% CO 2 . The filters were removed, washed with PBS, and air-dried. Filters were placed into 48-well plates. The lower portion of the chamber was filled with Medium 199 (Life TechnologieseInvitrogen) with 1% fetal bovine serum. PMCs (1 Â 10 5 cells) treated with TGF-b1 alone, with TGF-b1 and either CDDO-Im, CORM-2, or hemin, or with no treatment (control) were seeded into the upper chamber and incubated for 6 hours at 37 C. At the end of incubation, medium from the upper well was discarded. The upper sides of the filters were scraped to remove adherent cells. The filters were removed, and cells were fixed in formalin and stained with 20% Giemsa stain (catalog no. 48900, Fluka; Sigma-Aldrich). The number of cells that migrated was quantified by counting the number of cells on the distal surface of the filter under an optical microscope. The results are expressed as the haptotactic index [ie, the number of cells visualized per 20 high-power (Â40) fields]. Coating the filters with TGF-b1 acts as an attractant for the PMCs.
Explanted Lungs
Sixteen lungs from 16 patients with IPF, eight lungs from eight patients with COPD, two lungs from two patients with cystic fibrosis, and one lung from one patient with pulmonary arterial hypertension, were preserved after lung transplantation at the University of Alabama at Birmingham (Birmingham, AL), with informed consent. PMCs from explanted lungs were obtained by surface scraping of the visceral pleura and used in passages 2 to 4. PMCs expressed calretinin, mesothelin, and WT-1. Lung specimens were fixed in formalin, embedded in paraffin, and sectioned with a microtome before immunohistochemical staining on standard microscope slides.
Imaging
For fluorescence imaging, an Olympus BX51 microscope was used (40Â lens, numerical aperture of 1.3; Olympus America, Center Valley, PA). The fluorochromes used were as follows: for green fluorescent protein (GFP), Alexa Fluor 488 anti-chicken; for smooth muscle actin, Alexa Fluor 594 antimouse (Life TechnologieseInvitrogen). DAPI was used as a nuclear counterstain. A Retiga camera was used (12-bit color; QImaging, Surrey, BC, Canada) with light microscopy and Bioquant Osteo 2009 (Bioquant Image Analysis, Nashville, TN). For immunohistochemistry, an Axiovert 200M light microscope was used (40Â lens, numerical aperture 1.3; Carl Zeiss, Göttingen, Germany), at room temperature, with glass slides and bright-field fluorochromes. Images were captured using a QImaging QIClick camera and Q Capture Pro version 7 software (QImaging, Surrey, BC, Canada).
All human and animal studies were approved by the Institutional Review Board at the University of Alabama at Birmingham. Written informed consent was obtained from the participants before inclusion in the study.
Results
PMCs Are Present in Lung Explants from Patients with IPF
WT-1 is a zinc-finger protein that regulates many properties of the developing mesothelium. It is expressed in mesoderm-derived tissue, including normal pleural mesothelium, but is absent in normal lung, making it an ideal marker of PMCs. WT-1eexpressing PMCs have been shown to migrate into the lung parenchyma to form smooth muscle cells of the vascular wall and other cells of the lung mesenchyme during mouse lung development. 16 The major role of WT-1 in mesenchymal differentiation and development has implications for lung pathology, including pulmonary fibrosis. In the present study, using immunohistochemistry, we have demonstrated the abnormal presence of WT-1 þ cells within the parenchyma of an explanted lung from a representative patient with IPF, one of the 16 explanted lungs that underwent immunohistochemistry for WT-1 (Figure 1 ). WT-1 þ cells were absent from the explanted lungs of patients with non-IPF interstitial lung disease, cystic fibrosis, and chronic obstructive pulmonary disease (data not shown).
HO-1 Induction or Treatment with a CO-Releasing Molecule Inhibits PMC Differentiation into Myofibroblasts in Response to TGF-b1 in Mouse PMCs
Treatment of mouse PMCs with TGF-b1 increased expression of the myofibroblast marker a-smooth muscle actin (a-SMA) and NADPH oxidase-4 (NOX-4). NOX-4 has been shown to mediate myofibroblast activation and fibrogenic responses to lung injury. NOX-4edependent generation of hydrogen peroxide is required for TGF-b1einduced myofibroblast differentiation, extracellular matrix production, and contractility. 17 CDDO-Im, a synthetic triterpenoid, is a multifunctional molecule with antiproliferative, antidifferentiating, and anti-inflammatory activities that at nanomolar concentrations induces the expression of HO-1. 18 To investigate the effects of HO-1 induction on PMC differentiation and fibrosis, we treated mouse PMCs with TGF-b1 with and without 
HO-1 Induction and CO Inhibit PMC Contractility
We performed functional gel contraction assays to investigate the effects of HO-1 induction and CO on the response to TGF-b1 of PMCs from both healthy subjects and patients with IPF. PMCs were treated with TGF-b1 alone or were treated with either hemin, CDDO-Im, or CORM-2 before TGF-b1. In normal human PMCs, gel contraction was significantly decreased in control and in all three cotreatments, compared with TGF-b1 alone ( Figure 3A) . The PMCs from patients with IPF exhibited inherent contractility, even without TGF-b1 treatment, with no significant difference in gel area (a surrogate for PMC contractility) between control PMCs and TGF-b1etreated PMCs from patients with IPF. Cotreatment with hemin and TGF-b1, but not with CDDO-Im and TGF-b1, caused a significant increase in gel area; the addition of CORM-2 to TGFb1etreated IPF PMCs likewise caused a significant increase in gel area. These findings suggest reversion to a more normal PMC phenotype ( Figure 3B ). The data demonstrate a role for HO-1 induction or CO in preventing the contractile phenotype of normal PMCs treated with TGF-b1 and for reversing contractility in PMCs from patients with IPF.
HO-1 Induction and CO Prevent PMC Haptotaxis in Normal PMCs and PMCs from Patients with IPF
Haptotaxis assays were performed in Transwell migration chambers. Haptotaxis (ie, cell movement in response to gradients immobilized on a substratum) is distinct from chemotaxis, which is defined as cell migration along a concentration gradient of solubilized molecules. Haptotaxis more closely represents cell movement in the extracellular matrix. Normal PMCs (1 Â 10 5 cells) were treated with TGF-b1 alone, or with CDDO-Im, CORM-2, or hemin treatment followed by TGF-b1; untreated cells were used as control. The number of migrated cells was quantified, and data were expressed as the haptotactic index. Treatment with TGF-b1 caused significant haptotaxis, which was inhibited by CDDOIm, CORM-2, and hemin ( Figure 4A ). Haptotaxis assays with IPF PMCs, performed as described above, demonstrated increased baseline haptotaxis, along with increased haptotaxis after treatment with TGF-b1 that was significantly inhibited by hemin or CORM-2 cotreatment, but not by CDDO-Im ( Figure 4B ).
HO-1 Deficiency Potentiates Pleural and Subpleural Fibrosis in Mice
To further investigate the role of HO-1 in vivo in pleural and parenchymal fibrosis, we administered intrapleural bleomycin to Hmox À/À and Hmox þ/þ mice. Trichrome staining for collagen and H&E staining demonstrated a more robust pleural fibrotic response in HO-1edeficient mice, compared with wild-type mice ( Figure 5 ).
Mouse PMCs Undergo MMT and Migrate into the Lung Parenchyma after Intratracheal TGF-b1
To track PMC migration, we used heterozygotic mice recombinant for GFP driven by the WT-1 promoter. At 24 hours after intratracheal TGF-b1 treatment, we observed GFP þ cells inside the lung parenchyma ( Figure 6A ). The 
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þ cells costain for a-SMA, further supporting the concept that PMCs have not only migrated into the lung in response to inhaled stimuli, but have also undergone differentiation to express a myofibroblast phenotype ( Figure 6B ).
Intrapleural HO-1 Induction with CDDO-Im Prevents PMC Migration after Inhaled Fibrogenic Stimulus in Mice
To test the effects of pleural HO-1 induction on parenchymal PMC migration and fibrosis, we treated six wildtype mice with either intratracheal bleomycin alone or intratracheal bleomycin combined with intrapleural CDDOIm. Control mice treated with intratracheal bleomycin alone exhibited WT-1 þ cells along the pleura and in the parenchyma at 21 days after bleomycin treatment. Mice treated with intrapleural CDDO-Im at day 3 after bleomycin treatment exhibited WT-1 staining exclusively along the pleura at 21 days after bleomycin treatment ( Figure 7 ). Intrapleural HO-1 induction thus prevented parenchymal PMC migration in response to an inhaled fibrotic stimulus.
Hemin, CORM-2, and CDDO-Im Inhibit Myofibroblast Marker Expression in PMCs from Patients with IPF
We measured expression of a-SMA, NOX-4, and HO-1 in PMCs from patients with IPF, both before and after treatment with TGF-b1, with or without hemin, CORM-2, or CDDO-Im treatment. PMCs from IPF patients exhibited a predisposition to robustly express NOX-4 and a-SMA at baseline and also after TGF-b1. Treatment with hemin, CORM-2, or CDDO-Im decreased expression of myofibroblast markers (Figure 8) . Interestingly, the induction of HO-1 in IPF PMCs appeared less robust than in similar 
Discussion
The subpleural distribution of fibrosis in IPF is unexplained. Morphometric analysis of histological sections of usual interstitial pneumonia from patients with IPF using threedimensional reconstruction shows the fibroblastic foci of usual interstitial pneumonia at the leading edge of a reticulum that extends from the pleura to the underlying parenchyma. 3 In another study, carbon particles administered to the chest cavity of mice along with intratracheal bleomycin resulted in severe pleural fibrosis. 19 This was associated with progressive subpleural fibrosis, similar to IPF. The authors concluded that the PMCs had acquired myofibroblast characteristics and that the matrix accumulation within the subpleural area had evolved through mesothelialefibroblastoid transformation.
The origin of the myofibroblast in IPF is uncertain. These pathogenic cells have been variously proposed to be derived from local mesenchymal cells, circulating fibroblasts, and epithelial cells that have undergone EMT. 20 In experimental models of pulmonary fibrosis, both EMT and bone marrow progenitors contribute to the fibroblast population. However, neither is a principal contributor to lung myofibroblasts. 21 The role of EMT and MMT in development and disease pathogenesis is established in other organs. HO-1 deficiency is associated with increased fibrosis, tubular TGF-b1 expression, inflammation, and enhanced EMT in obstructive kidney disease. 12 Recently, our research group reported PMC transformation into myofibroblasts and haptotactic migration in response to TGF-b1 in vitro.
7 Subsequently, our research group reported that PMCs migrate into the lung and display myofibroblast phenotypic markers; importantly, their presence correlated with the severity of fibrosis in IPF. 8 Serosal surfaces play an integral role in organogenesis and development. The mesothelial covering of the embryonic heart is a major source of cells to the coronary system. muscle cells and possibly also alveolar myofibroblasts and interstitial fibroblasts. 16 The authors suggested a common mechanism linking the development of coelomic organs with the maturation of the internal vasculature and postulated that adult PMCs are multipotent and possibly able to give rise to mesenchymal cells during injury, repair, or pathology. A subsequent study provided definitive evidence of the multipotent capacity of PMCs by demonstrating differentiation into osteoblast and adipocyte-like cells when exposed to an appropriate growth medium; the authors concluded that mesothelial cell differentiation is a potential source of the different tissue types found in malignant mesothelioma and other serosal pathologies, suggesting potential roles in regenerative therapies. 27 Is it noteworthy that WT-1eexpressing cells have a capacity to switch between mesenchymal and epithelial states. 28 This may indicate that WT-1 expression is necessary, but not sufficient, to permit the transition between mesothelial and mesenchymal phenotypes.
The pleura is a metabolically active monolayer of mesothelial cells that intimately approximates the lung parenchyma. This proximity of PMCs to the underlying lung ideally positions them to respond to signals released during parenchymal stress, whether mechanical, inflammatory, or infectious. In fact, a recent magnetic resonance imaging study in rats demonstrated the appearance of a marked inflammatory signal arising from the pleura 6 hours after inhaled antigen or endotoxin; the inflammatory signal correlated with a histological analysis revealing severe pleural cavity edema. 29 The reciprocal communication that occurs between the pleura and parenchyma in the developing lung may therefore continue in the adult and contribute to disease.
With the present study, we have demonstrated in vitro PMC differentiation and acquisition of a myofibroblast phenotype, as evidenced by expression of mesenchymal markers and functional assays, including haptotaxis and gel contraction, in response to TGF-b1 treatment. Furthermore, induction of HO-1 or treatment with CO abrogated PMC differentiation and/or MMT and parenchymal migration. HO-1edeficient mice also experienced greater pleural fibrosis in response to intrapleural bleomycin treatment, compared with wild-type mice.
WT-1 þ cells were present in lung explants from patients with IPF, but not in explants from patients with cystic fibrosis or chronic obstructive pulmonary disease (data not shown). Importantly, the present study is the first to demonstrate significant phenotypic and functional differences in PMCs from patients with IPF, compared with normal PMCs. Strikingly, IPF PMCs displayed a propensity to express the myofibroblast-specific marker a-SMA, as well as NOX-4, a known driver of myofibroblast activation and fibrotic responses to lung injury. 17 Not only did IPF PMCs express myofibroblast markers, but they also exhibited increased contractility and propensity for migration. Inducibility of HO-1 expression in PMCs from patients with IPF was lower, compared with normal PMCs, suggesting an inherent or acquired defect. Abnormalities or deficiencies in HO-1 expression or activity in IPF may predispose these patients to fibroblast proliferation and progressive disease.
There is a potential to use HO-1 modulation and CO as therapies for fibrotic lung disease. Studies in other organ systems have shown, using mouse models, that HO-1 induction opposes pathological postinfarction left ventricular remodeling 30 and prevents the progression of liver fibrosis.
31
CO also suppresses bleomycin-induced lung fibrosis in mice. 32 Pioneering work by Ryter and Choi 33 has opened the exciting prospect of translational applications for HO-1 research. In fact, a phase 2 study is recruiting participants (Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis; http://www.clinicaltrials.gov/ct2/show/ NCT01214187, last accessed February 9, 2013).
In the present study, treatment of PMCs with CO in the form of CORM-2 or hemin not only prevented or reversed the expression of a-SMA and NOX-4, but also significantly attenuated the contractile phenotype of IPF PMCs and PMC haptotaxis. It is important to note that, although hemin and CORM-2 reversed the increased gel contraction and haptotaxis seen in TGF-b1etreated PMCs, CDDO-Im was unable to rescue the TGF-b1etreated IPF PMCs. This suggests that HO-1 induction alone may be insufficient to protect against fibrosis in IPF. Perhaps an inherent or acquired HO-1 substrate deficiency also predisposes to IPF disease. The downstream products of the heme oxygenase reaction may hold more promise for modulating PMC fibrotic phenotypic expression. The present findings raise the possibility that intrapleural modulation of HO-1 or delivery of CO to the pleural space could contribute to novel strategies in the treatment of IPF by inhibiting PMC differentiation and parenchymal trafficking. ajp.amjpathol.org -The American Journal of Pathology
